Literature DB >> 15221879

Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients.

Lan Zhou1, John McConville, Vinay Chaudhry, Robert N Adams, Richard L Skolasky, Angela Vincent, Daniel B Drachman.   

Abstract

We assayed cryopreserved sera from 38 acetylcholine receptor (AChR) antibody-negative patients with myasthenia gravis (MG) who were followed clinically for muscle-specific tyrosine kinase (MuSK) antibodies and analyzed and compared their clinical characteristics. None of 13 sera from patients with purely ocular MG were positive. Sera from 10 of 25 patients (40%) with generalized MG were positive for MuSK antibodies. The age at onset of myasthenic symptoms was significantly earlier in MuSK antibody-positive patients (P = 0.02). MuSK antibodies were present in AChR antibody-negative patients of either gender, with virtually identical prevalence in women (41.2%) and men (37.5%). The distribution of weakness more commonly involved neck muscles in MuSK antibody-positive patients, and limb muscles in MuSK antibody-negative patients. Patients responded to immunosuppressive treatment regardless of whether MuSK antibody was present. We conclude that MuSK antibodies are present and diagnostically useful in a subset of myasthenic patients without AChR antibodies. Although the distribution of weakness differs somewhat depending on whether MuSK antibodies are present, responses to anticholinesterase and immunosuppressive treatments are similar. Copyright 2004 Wiley Periodicals, Inc. Muscle Nerve 30: 55-60, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15221879     DOI: 10.1002/mus.20069

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  28 in total

1.  MuSK-antibody positive pure ocular myasthenia gravis.

Authors:  Frank Hanisch; Katharina Eger; Stephan Zierz
Journal:  J Neurol       Date:  2005-11-29       Impact factor: 4.849

2.  Anti-MuSK antibodies in a case of ocular myasthenia gravis.

Authors:  D L H Bennett; K R Mills; P Riordan-Eva; P R J Barnes; M R Rose
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

3.  Granzyme B: evidence for a role in the origin of myasthenia gravis.

Authors:  L Casciola-Rosen; A Miagkov; K Nagaraju; F Askin; L Jacobson; A Rosen; D B Drachman
Journal:  J Neuroimmunol       Date:  2008-08-03       Impact factor: 3.478

4.  Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis.

Authors:  Daniel B Drachman; Robert N Adams; Rong Hu; Richard J Jones; Robert A Brodsky
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

5.  Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.

Authors:  David P Richman; Kayoko Nishi; Stuart W Morell; Jolene Mi Chang; Michael J Ferns; Robert L Wollmann; Ricardo A Maselli; Joachim Schnier; Mark A Agius
Journal:  Arch Neurol       Date:  2011-12-12

Review 6.  Current approach to seronegative myasthenia.

Authors:  Zohar Argov
Journal:  J Neurol       Date:  2010-09-18       Impact factor: 4.849

7.  Animal models of antimuscle-specific kinase myasthenia.

Authors:  David P Richman; Kayoko Nishi; Michael J Ferns; Joachim Schnier; Peter Pytel; Ricardo A Maselli; Mark A Agius
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

Review 8.  Treatment of Myasthenia Gravis in the Aged.

Authors:  Nuha M Alkhawajah; Joel Oger
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

9.  Induction of myasthenia by immunization against muscle-specific kinase.

Authors:  Kazuhiro Shigemoto; Sachiho Kubo; Naoki Maruyama; Naohito Hato; Hiroyuki Yamada; Chen Jie; Naoto Kobayashi; Katsumi Mominoki; Yasuhito Abe; Norifumi Ueda; Seiji Matsuda
Journal:  J Clin Invest       Date:  2006-03-23       Impact factor: 14.808

10.  Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.

Authors:  Shin Joong Oh
Journal:  J Clin Neurol       Date:  2009-06-30       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.